Michael S. Ominsky
Ascendis Pharma (Denmark)(DK)
Publications by Year
Research Areas
Bone health and osteoporosis research, Bone Metabolism and Diseases, Bone health and treatments, Connective tissue disorders research, Thyroid and Parathyroid Surgery
Most-Cited Works
- → Dickkopf-1 is a master regulator of joint remodeling(2007)1,271 cited
- → Targeted Deletion of the Sclerostin Gene in Mice Results in Increased Bone Formation and Bone Strength(2008)937 cited
- → Sclerostin Antibody Treatment Increases Bone Formation, Bone Mass, and Bone Strength in a Rat Model of Postmenopausal Osteoporosis(2008)778 cited
- → Denosumab, a Fully Human Monoclonal Antibody to RANKL, Inhibits Bone Resorption and Increases BMD in Knock-In Mice That Express Chimeric (Murine/Human) RANKL(2008)432 cited
- → Dkk1-mediated inhibition of Wnt signaling in bone results in osteopenia(2006)431 cited
- → Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength(2010)412 cited
- → Sclerostin and Dickkopf-1 as Therapeutic Targets in Bone Diseases(2012)398 cited
- → Inhibition of sclerostin by monoclonal antibody enhances bone healing and improves bone density and strength of nonfractured bones(2010)265 cited
- → A bispecific antibody targeting sclerostin and DKK-1 promotes bone mass accrual and fracture repair(2016)251 cited
- → Effects of denosumab on bone histomorphometry: The FREEDOM and STAND studies(2010)250 cited